{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T05:23:50Z","timestamp":1705555430042},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["21K08263"],"award-info":[{"award-number":["21K08263"]}]},{"name":"the Japan Foundation for Applied Enzymes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global pandemic. Although several vaccines targeting SARS-CoV-2 spike proteins protect against COVID-19 infection, mutations affecting virus transmissibility and immune evasion potential have reduced their efficacy, leading to the need for a more efficient strategy. Available clinical evidence regarding COVID-19 suggests that endothelial dysfunction with thrombosis is a central pathogenesis of progression to systemic disease, in which overexpression of plasminogen activator inhibitor-1 (PAI-1) may be important. Here we developed a novel peptide vaccine against PAI-1 and evaluated its effect on lipopolysaccharide (LPS)-induced sepsis and SARS-CoV-2 infection in mice. Administration of LPS and mouse-adapted SARS-CoV-2 increased serum PAI-1 levels, although the latter showed smaller levels. In an LPS-induced sepsis model, mice immunized with PAI-1 vaccine showed reduced organ damage and microvascular thrombosis and improved survival compared with vehicle-treated mice. In plasma clot lysis assays, vaccination-induced serum IgG antibodies were fibrinolytic. However, in a SARS-CoV-2 infection model, survival and symptom severity (i.e., body weight reduction) did not differ between vaccine- and vehicle-treated groups. These results indicate that although PAI-1 may promote the severity of sepsis by increasing thrombus formation, it might not be a major contributor to COVID-19 exacerbation.<\/jats:p>","DOI":"10.1038\/s41598-023-30305-8","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T10:02:59Z","timestamp":1677060179000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection"],"prefix":"10.1038","volume":"13","author":[{"given":"Takashin","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Azegami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Kiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Uraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Hishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Nakamichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erina","family":"Sugita-Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Yoshida-Hama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"30305_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470\u2013473 (2020).","journal-title":"Lancet"},{"key":"30305_CR2","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19): situation report 51. World Health Organization 2020. https:\/\/apps.who.int\/iris\/handle\/10665\/331475 (Accessed 30 July 2022)."},{"key":"30305_CR3","unstructured":"World Health Organization. COVID-19 weekly epidemiological update, edition 99, 6 July 2022. World Health Organization 2022. https:\/\/apps.who.int\/iris\/handle\/10665\/359148 (Accessed 30 July 2022)."},{"key":"30305_CR4","doi-asserted-by":"publisher","first-page":"e1003501","DOI":"10.1371\/journal.pmed.1003501","volume":"17","author":"MS Kim","year":"2020","unstructured":"Kim, M. S., An, M. H., Kim, W. J. & Hwang, T. H. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 17, e1003501. https:\/\/doi.org\/10.1371\/journal.pmed.1003501 (2020).","journal-title":"PLoS Med."},{"key":"30305_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","volume":"20","author":"M Jeyanathan","year":"2020","unstructured":"Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615\u2013632 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"30305_CR6","doi-asserted-by":"publisher","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","volume":"11","author":"V Rotshild","year":"2021","unstructured":"Rotshild, V., Hirsh-Raccah, B., Miskin, I., Muszkat, M. & Matok, I. Comparing the clinical efficacy of COVID-19 vaccines: A systematic review and network meta-analysis. Sci. Rep. 11, 22777. https:\/\/doi.org\/10.1038\/s41598-021-02321-z (2021).","journal-title":"Sci. Rep."},{"key":"30305_CR7","doi-asserted-by":"publisher","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","volume":"376","author":"AS Lauring","year":"2022","unstructured":"Lauring, A. S. et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ 376, e069761. https:\/\/doi.org\/10.1136\/bmj-2021-069761 (2022).","journal-title":"BMJ"},{"key":"30305_CR8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"30305_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"30305_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/07853890.2021.1884744","volume":"53","author":"HC Park","year":"2021","unstructured":"Park, H. C. et al. Clinical outcomes of initially asymptomatic patients with COVID-19: A Korean nationwide cohort study. Ann. Med. 53, 357\u2013364 (2021).","journal-title":"Ann. Med."},{"key":"30305_CR11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019. JAMA 324, 782\u2013793 (2020).","journal-title":"JAMA"},{"key":"30305_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jcrc.2021.12.007","volume":"68","author":"S Brinkman","year":"2022","unstructured":"Brinkman, S. et al. Comparison of outcome and characteristics between 6343 COVID-19 patients and 2256 other community-acquired viral pneumonia patients admitted to Dutch ICUs. J. Crit. Care. 68, 76\u201382 (2022).","journal-title":"J. Crit. Care."},{"key":"30305_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ahj.2020.10.075","volume":"231","author":"NR Milowitz","year":"2021","unstructured":"Milowitz, N. R. et al. Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19. Am. Heart J. 231, 93\u201395 (2021).","journal-title":"Am. Heart J."},{"key":"30305_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","volume":"21","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319\u2013329 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"30305_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1152\/physrev.00035.2020","volume":"101","author":"K Sriram","year":"2021","unstructured":"Sriram, K. & Insel, P. A. Inflammation and thrombosis in COVID-19 pathophysiology: Proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol. Rev. 101, 545\u2013567 (2021).","journal-title":"Physiol. Rev."},{"key":"30305_CR16","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/jth.14849","volume":"18","author":"JM Connors","year":"2020","unstructured":"Connors, J. M. & Levy, J. H. Thromboinflammation and the hypercoagulability of COVID-19. J. Thromb. Haemost. 18, 1559\u20131561 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"30305_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M20-2003","volume":"173","author":"D Wichmann","year":"2020","unstructured":"Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Ann. Intern. Med. 173, 268\u2013277 (2020).","journal-title":"Ann. Intern. Med."},{"key":"30305_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N. Engl. J. Med. 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"30305_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ijid.2021.06.051","volume":"117","author":"A Wibowo","year":"2022","unstructured":"Wibowo, A., Pranata, R., Lim, M. A., Akbara, M. R. & Martha, J. W. Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: A systematic review and meta-analysis. Int. J. Infect. Dis. 117, 267\u2013273 (2022).","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"30305_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/bloodadvances.2020003736","volume":"5","author":"E Villa","year":"2021","unstructured":"Villa, E. et al. Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. Blood Adv. 5(5), 662\u2013673 (2021).","journal-title":"Blood Adv."},{"key":"30305_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12959-021-00284-9","volume":"19","author":"X Xiong","year":"2021","unstructured":"Xiong, X., Chi, J. & Gao, Q. Prevalence and risk factors of thrombotic events on patients with COVID-19: A systematic review and meta-analysis. Thromb. J. 19, 32. https:\/\/doi.org\/10.1186\/s12959-021-00284-9 (2021).","journal-title":"Thromb. J."},{"key":"30305_CR22","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1038\/s41418-020-00633-7","volume":"27","author":"T Matsuyama","year":"2020","unstructured":"Matsuyama, T., Kubli, S. P., Yoshinaga, S. K., Pfeffer, K. & Mak, T. W. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 27, 3209\u20133225 (2020).","journal-title":"Cell Death Differ."},{"key":"30305_CR23","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms22031283","volume":"22","author":"HC Kwaan","year":"2021","unstructured":"Kwaan, H. C. & Lindholm, P. F. The central role of fibrinolytic response in COVID-19-A hematologist\u2019s perspective. Int. J. Mol. Sci. 22, 1283. https:\/\/doi.org\/10.3390\/ijms22031283 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"30305_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tips.2021.03.006","volume":"42","author":"TF Kellici","year":"2021","unstructured":"Kellici, T. F., Pilka, E. S. & Bodkin, M. J. Therapeutic potential of targeting plasminogen activator inhibitor-1 in COVID-19. Trends Pharmacol. Sci. 42, 431\u2013433 (2021).","journal-title":"Trends Pharmacol. Sci."},{"key":"30305_CR25","doi-asserted-by":"publisher","first-page":"22351","DOI":"10.1073\/pnas.2010229117","volume":"117","author":"S Kang","year":"2020","unstructured":"Kang, S. et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc. Natl. Acad. Sci. USA. 117, 22351\u201322356 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"30305_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1165\/rcmb.2021-0208ED","volume":"65","author":"SS Khan","year":"2021","unstructured":"Khan, S. S. The central role of PAI-1 in COVID-19: Thrombosis and beyond. Am. J. Respir. Cell Mol. Biol. 65, 238\u2013240 (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"30305_CR27","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3389\/fimmu.2018.01218","volume":"9","author":"TL Tipoe","year":"2018","unstructured":"Tipoe, T. L. et al. Plasminogen activator inhibitor 1 for predicting sepsis severity and mortality outcomes: A systematic review and meta-analysis. Front. Immunol. 9, 1218. https:\/\/doi.org\/10.3389\/fimmu.2018.01218 (2018).","journal-title":"Front. Immunol."},{"key":"30305_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/ars.2007.1903","volume":"10","author":"RM Liu","year":"2008","unstructured":"Liu, R. M. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid. Redox Signal. 10, 303\u2013319 (2008).","journal-title":"Antioxid. Redox Signal."},{"key":"30305_CR29","first-page":"1417","volume":"12","author":"S Hammer","year":"2021","unstructured":"Hammer, S. et al. Severe SARS-CoV-2 infection inhibits fibrinolysis leading to changes in viscoelastic properties of blood clot: A descriptive study of fibrinolysis in COVID-19. Thromb. Haemost. 12, 1417\u20131426 (2021).","journal-title":"Thromb. Haemost."},{"key":"30305_CR30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41598-020-80010-z","volume":"11","author":"Y Zuo","year":"2021","unstructured":"Zuo, Y. et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci. Rep. 11, 1580. https:\/\/doi.org\/10.1038\/s41598-020-80010-z (2021).","journal-title":"Sci. Rep."},{"key":"30305_CR31","doi-asserted-by":"publisher","first-page":"107602962199909","DOI":"10.1177\/1076029621999099","volume":"27","author":"S Lopez-Castaneda","year":"2021","unstructured":"Lopez-Castaneda, S. et al. Inflammatory and prothrombotic biomarkers associated with the severity of COVID-19 infection. Clin. Appl. Thromb. Hemost. 27, 1076029621999099. https:\/\/doi.org\/10.1177\/1076029621999099 (2021).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"30305_CR32","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.vaccine.2013.02.001","volume":"31","author":"MF Bachmann","year":"2013","unstructured":"Bachmann, M. F. & Whitehead, P. Active immunotherapy for chronic diseases. Vaccine. 31, 1777\u20131784 (2013).","journal-title":"Vaccine."},{"key":"30305_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2052-0492-2-20","volume":"2","author":"H Asakura","year":"2014","unstructured":"Asakura, H. Classifying types of disseminated intravascular coagulation: Clinical and animal models. J. Intensive Care. 2, 20. https:\/\/doi.org\/10.1186\/2052-0492-2-20 (2014).","journal-title":"J. Intensive Care."},{"key":"30305_CR34","doi-asserted-by":"publisher","first-page":"626553","DOI":"10.3389\/fmicb.2021.626553","volume":"12","author":"S Shou","year":"2021","unstructured":"Shou, S. et al. Animal models for COVID-19: Hamsters, mouse, ferret, mink, tree shrew, and non-human primates. Front. Microbiol. 12, 626553. https:\/\/doi.org\/10.3389\/fmicb.2021.626553 (2021).","journal-title":"Front. Microbiol."},{"key":"30305_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","volume":"40","author":"S Hojyo","year":"2020","unstructured":"Hojyo, S. et al. How COVID-19 induces cytokine storm with high mortality. Inflamm. Regen. 40, 37. https:\/\/doi.org\/10.1186\/s41232-020-00146-3 (2020).","journal-title":"Inflamm. Regen."},{"key":"30305_CR36","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/01.CIR.0000161823.55935.BE","volume":"111","author":"G Rega","year":"2005","unstructured":"Rega, G. et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 111, 1938\u20131945 (2005).","journal-title":"Circulation"},{"key":"30305_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","volume":"588","author":"J Carvelli","year":"2020","unstructured":"Carvelli, J. et al. Association of COVID-19 inflammation with activation of the C5a\u2013C5aR1 axis. Nature 588, 146\u2013150 (2020).","journal-title":"Nature"},{"key":"30305_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1165\/rcmb.2020-0544OC","volume":"65","author":"M Han","year":"2021","unstructured":"Han, M. & Pandey, D. ZMPSTE24 regulates SARS-CoV-2 spike protein-enhanced expression of endothelial PAI-1. Am. J. Respir. Cell Mol. Biol. 65, 300\u2013308 (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"30305_CR39","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1111\/dom.14124","volume":"22","author":"AK Singh","year":"2020","unstructured":"Singh, A. K. et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes. Metab. 22, 1915\u20131924 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"30305_CR40","doi-asserted-by":"publisher","first-page":"eaao1617","DOI":"10.1126\/sciadv.aao1617","volume":"3","author":"SS Khan","year":"2017","unstructured":"Khan, S. S. et al. A null mutation in SERPINE1 protects against biological aging in humans. Sci. Adv. 3, eaao1617. https:\/\/doi.org\/10.1126\/sciadv.aao1617 (2017).","journal-title":"Sci. Adv."},{"key":"30305_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1182\/blood.V90.1.204.204_204_208","volume":"90","author":"WP Fay","year":"1997","unstructured":"Fay, W. P., Parker, A. C., Condrey, L. R. & Shapiro, A. D. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 90, 204\u2013208 (1997).","journal-title":"Blood"},{"key":"30305_CR42","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/35038119","volume":"407","author":"JA Huntington","year":"2000","unstructured":"Huntington, J. A., Read, R. J. & Carrell, R. W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407, 923\u2013926 (2000).","journal-title":"Nature"},{"key":"30305_CR43","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.thromres.2007.09.005","volume":"122","author":"AE Tsantes","year":"2008","unstructured":"Tsantes, A. E. et al. The effect of the plasminogen activator inhibitor-1 4G\/5G polymorphism on the thrombotic risk. Thromb. Res. 122, 736\u2013742 (2008).","journal-title":"Thromb. Res."},{"key":"30305_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1055\/s-0038-1661449","volume":"55","author":"EK Kruithof","year":"1986","unstructured":"Kruithof, E. K., Tran-Thang, C. & Bachmann, F. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb. Haemost. 55, 65\u201369 (1986).","journal-title":"Thromb. Haemost."},{"key":"30305_CR45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/355270a0","volume":"355","author":"J Mottonen","year":"1992","unstructured":"Mottonen, J. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 355, 270\u2013273 (1992).","journal-title":"Nature"},{"key":"30305_CR46","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41598-019-38842-x","volume":"9","author":"KA Vousden","year":"2019","unstructured":"Vousden, K. A. et al. Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1. Sci. Rep. 9, 1605. https:\/\/doi.org\/10.1038\/s41598-019-38842-x (2019).","journal-title":"Sci. Rep."},{"key":"30305_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biologicals.2020.08.001","volume":"67","author":"R Kashiwagi","year":"2020","unstructured":"Kashiwagi, R., Sato, R., Masumoto, M., Yoshino, M. & Tanaka, H. AS3288802, a highly selective antibody to active plasminogen activator inhibitor-1 (PAI-1), exhibits long efficacy duration in cynomolgus monkeys. Biologicals 67, 21\u201328 (2020).","journal-title":"Biologicals"},{"key":"30305_CR48","doi-asserted-by":"publisher","first-page":"e0120728","DOI":"10.1371\/journal.pone.0120728","volume":"10","author":"KK Gupta","year":"2015","unstructured":"Gupta, K. K., Donahue, D. L., Sandoval-Cooper, M. J., Castellino, F. J. & Ploplis, V. A. Abrogation of plasminogen activator inhibitor-1-vitronectin interaction ameliorates acute kidney injury in murine endotoxemia. PLoS ONE 10, e0120728. https:\/\/doi.org\/10.1371\/journal.pone.0120728 (2015).","journal-title":"PLoS ONE"},{"key":"30305_CR49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.bbrc.2016.06.065","volume":"477","author":"KK Gupta","year":"2016","unstructured":"Gupta, K. K., Xu, Z., Castellino, F. J. & Ploplis, V. A. Plasminogen activator inhibitor-1 stimulates macrophage activation through Toll-like Receptor-4. Biochem. Biophys. Res. Commun. 477, 503\u2013508 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"30305_CR50","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1111\/jth.12032","volume":"10","author":"R Narasaki","year":"2012","unstructured":"Narasaki, R. et al. The vitronectin-binding domain of plasminogen activator inhibitor-1 plays an important functional role in lipopolysaccharide-induced lethality in mice. J. Thromb. Haemost. 10, 2618\u20132621 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"30305_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/SHK.0000000000001823","volume":"57","author":"S Fern\u00e1ndez","year":"2022","unstructured":"Fern\u00e1ndez, S. et al. Distinctive biomarker features in the endotheliopathy of COVID-19 and septic syndromes. Shock 57, 95\u2013105 (2022).","journal-title":"Shock"},{"key":"30305_CR52","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.3390\/jcm9092875","volume":"9","author":"Y Umemura","year":"2020","unstructured":"Umemura, Y. et al. Hematological phenotype of COVID-19-induced coagulopathy: Far from typical sepsis-induced coagulopathy. J. Clin. Med. 9, 2875. https:\/\/doi.org\/10.3390\/jcm9092875 (2020).","journal-title":"J. Clin. Med."},{"key":"30305_CR53","doi-asserted-by":"publisher","first-page":"e12525","DOI":"10.1002\/rth2.12525","volume":"5","author":"RA Campbell","year":"2021","unstructured":"Campbell, R. A. et al. Comparison of the coagulopathies associated with COVID-19 and sepsis. Res. Pract. Thromb. Haemost. 5, e12525. https:\/\/doi.org\/10.1002\/rth2.12525 (2021).","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"30305_CR54","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cell.2015.01.040","volume":"160","author":"M Dittmann","year":"2015","unstructured":"Dittmann, M. et al. A serpin shapes the extracellular environment to prevent influenza A virus maturation. Cell 160, 631\u2013643 (2015).","journal-title":"Cell"},{"key":"30305_CR55","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/jth.14960","volume":"18","author":"RL Medcalf","year":"2020","unstructured":"Medcalf, R. L., Keragala, C. B. & Myles, P. S. Fibrinolysis and COVID-19: A plasmin paradox. J. Thromb. Haemost. 18, 2118\u20132122 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"30305_CR56","doi-asserted-by":"publisher","first-page":"L247","DOI":"10.1152\/ajplung.00075.2011","volume":"301","author":"JW Zmijewski","year":"2011","unstructured":"Zmijewski, J. W. et al. Inhibition of neutrophil apoptosis by PAI-1. Am. J. Physiol. Lung Cell Mol. Physiol. 301, L247-254 (2011).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"30305_CR57","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jth.12565","volume":"12","author":"P Raeven","year":"2014","unstructured":"Raeven, P. et al. Systemic inhibition and liver-specific over-expression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice. J. Thromb. Haemost. 12, 958\u2013969 (2014).","journal-title":"J. Thromb. Haemost."},{"key":"30305_CR58","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/blood.V71.1.220.220","volume":"71","author":"PJ Declerck","year":"1988","unstructured":"Declerck, P. J. et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71, 220\u2013225 (1988).","journal-title":"Blood"},{"key":"30305_CR59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1083\/jcb.152.4.777","volume":"152","author":"K Bajou","year":"2001","unstructured":"Bajou, K. et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152, 777\u2013784 (2001).","journal-title":"J. Cell Biol."},{"key":"30305_CR60","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/j.1538-7836.2011.04288.x","volume":"9","author":"T Iwaki","year":"2011","unstructured":"Iwaki, T. et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J. Thromb. Haemost. 9, 1200\u20131206 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"30305_CR61","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412. https:\/\/doi.org\/10.1371\/journal.pbio.1000412 (2010).","journal-title":"PLoS Biol."},{"key":"30305_CR62","doi-asserted-by":"publisher","first-page":"11693","DOI":"10.1016\/S0021-9258(19)49751-2","volume":"267","author":"PJ Declerck","year":"1992","unstructured":"Declerck, P. J., De Mol, M., Vaughan, D. E. & Collen, D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J. Biol. Chem. 267, 11693\u201311696 (1992).","journal-title":"J. Biol. Chem."},{"key":"30305_CR63","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2337\/db20-1257","volume":"70","author":"T Azegami","year":"2021","unstructured":"Azegami, T. et al. Vaccination against receptor for advanced glycation end products attenuates the progression of diabetic kidney disease. Diabetes 70, 2147\u20132158 (2021).","journal-title":"Diabetes"},{"key":"30305_CR64","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1161\/ATVBAHA.115.306845","volume":"36","author":"N Yaoita","year":"2016","unstructured":"Yaoita, N. et al. Thrombin-activatable fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 36, 1293\u20131301 (2016).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"30305_CR65","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5493\/wjem.v2.i2.30","volume":"2","author":"Y Liu","year":"2012","unstructured":"Liu, Y., Jennings, N. L., Dart, A. M. & Du, X. J. Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice. World J. Exp. Med. 2, 30\u201336 (2012).","journal-title":"World J. Exp. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30305-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30305-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30305-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T22:03:43Z","timestamp":1677103423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30305-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["30305"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-30305-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"1 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3103"}}